Tiratricol
 | |
| Clinical data | |
|---|---|
| Synonyms | 3,3',5-triiodothyroacetic acid TRIAC |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | Presumed high |
| Metabolism | Hepatic glucuronidation |
| Excretion | Biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C14H9I3O4 |
| Molar mass | 621.932 g/mol |
|
WikiDoc Resources for Tiratricol |
|
Articles |
|---|
|
Most recent articles on Tiratricol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tiratricol at Clinical Trials.gov Clinical Trials on Tiratricol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tiratricol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tiratricol Discussion groups on Tiratricol Patient Handouts on Tiratricol Directions to Hospitals Treating Tiratricol Risk calculators and risk factors for Tiratricol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tiratricol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Tiratricol (also known as TRIAC) is a thyroid hormone analogue. It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.
Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[2][3]
Legal status
Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[4]
References
- ↑ Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]". Arq Bras Endocrinol Metabol (in Portuguese). 48 (1): 83–92. doi:/S0004-27302004000100010 Check
|doi=value (help). PMID 15611821. Template:PDFlink - ↑ "FDA Warns Against Consuming Dietary Supplements Containing Tiratricol" (Press release). U.S. Food and Drug Administration. November 21 2000. Check date values in:
|date=(help) - ↑ "Health Canada issues warning on products containing Tiratricol (TRIAC)" (Press release). Health Canada. December 2 1999. Check date values in:
|date=(help) - ↑ "Anvisa suspende Tiratricol" (in Portuguese). Brazilian Society of Endocrinology and Metabolism.
- Pages with script errors
- CS1 errors: DOI
- CS1 maint: Unrecognized language
- CS1 errors: dates
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Orphan drugs
- Endocrinology